Your AI-Trained Oncology Knowledge Connection!
This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.
Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.
Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.
Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.
